Nuwellis Announces Aquadex Software Update
Nuwellis (NASDAQ: NUWE) released a software update for the Aquadex SmartFlow ultrafiltration platform on April 21, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuwellis (NASDAQ: NUWE) released a software update for the Aquadex SmartFlow ultrafiltration platform on April 21, 2026. The update reduces ultrafiltration step size from 10 mL/hr to 5 mL/hr, adds a refined blood flow algorithm to reduce nuisance alarms, improves clotting visibility, and expands hourly therapy logs. The update targets improved usability and more precise fluid management for pediatric patients and is available to existing customers at no cost via standard deployment with field support.
Positive
- Ultrafiltration step size reduced to 5 mL/hr from 10 mL/hr
- Update available to existing customers at no cost
- Refined blood flow algorithm aimed to reduce nuisance alarms
- Expanded hourly data log with additional therapy parameters
Negative
- None.
Details
News Market Reaction – NUWE
On Apr 21, the day this news came out, NUWE closed 0.86% below the previous close.
Data tracked by StockTitan Argus for the Apr 21 session.
Key Figures
- New UF step size
- 5 mL/hr
- Updated Aquadex ultrafiltration adjustment for pediatric-focused fluid management
- Prior UF step size
- 10 mL/hr
- Previous Aquadex ultrafiltration adjustment granularity before software update
Historical Context
-
Rehiring three former employees to accelerate Aquadex commercial and clinical momentum.
-
Engaged CORE IR for PR, shareholder communications, and social media support.
-
Created dedicated South Texas commercial territory to strengthen hospital engagement.
-
Pediatric category reached ~50% of U.S. revenue across 47 centers in 2025.
-
Completed Rendiatech acquisition to add automated continuous kidney function monitoring.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ultrafiltration medical
cardiorenal medical
pediatric medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New release enhances usability and delivers more precise fluid management for pediatric patients
MINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience.
A key feature of the release is a more precise ultrafiltration adjustment capability, reducing the step size to 5 mL/hr from 10 mL/hr. This advancement is particularly important in pediatric care, where small-volume fluid shifts can have a significant clinical impact.
“The Aquadex software update reflects our commitment to continuous improvement driven by customer feedback and clinical need,” said Nuwellis’ CEO John Erb. “This release provides clinicians with greater control over fluid management – especially in pediatric patients, which represents our largest and fastest-growing customer category – while also making the system easier to use in demanding care environments.”
The update also includes enhancements aimed at improving ease-of-use of the device and therapy visibility, particularly for nursing staff managing day-to-day treatment. Key updates include:
- Refined blood flow algorithm designed to reduce nuisance alarms and improve flow stability;
- Enhanced blood flow resistance graph to provide earlier indication of potential filter clotting ; and
- Expanded hourly data log with additional therapy parameters to support clinical monitoring and documentation.
The software update is available to existing customers at no cost and can be deployed through standard update processes with support from Nuwellis’ field and service teams.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.